Antisoma Research Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: London United Kingdom (1988)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2003
NCT00856336
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (3)

Key: Antisoma Research (1) Acquired (2)

amonafide (4 trials)

cytarabine (cytosar-u) (4 trials)

daunorubicin (cerubidine) (1 trial)

Drugs in Phase 2 Trials (6)

as1411 (4 trials)

carboplatin (paraplatin) (1 trial)

letrozole (femara) (1 trial)

paclitaxel (taxol) (1 trial)

sontuzumab (1 trial)

vadimezan (3 trials)

Drugs in Phase 1 Trials (1)

as1409 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Leukemia (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lung Neoplasms (Phase 2)

Melanoma (Phase 1)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 10